---
schema_version: "secwatch.filing_event.v1"
accession: "0001613103-25-000078"
form_type: "8-K"
ticker: "MDT"
cik: "0001613103"
company_name: "Medtronic plc"
filed_at: "2025-05-21T23:59:59+00:00"
generated_at: "2026-05-20T22:32:56.197079+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Medtronic Q4 EPS $1.62 non-GAAP (+11%); to spin off Diabetes; dividend raised to $0.71

## Summary
- Q4 FY25 revenue $8.93B (+5.4% organic); non-GAAP EPS $1.62 (+11% as reported, +16% constant currency).
- Plans to spin off Diabetes business into standalone public company within 18 months via IPO/split-off; accretive to margins and EPS.
- Dividend raised to $0.71/quarter ($2.84 annual) — 48th consecutive annual increase; payable July 11, 2025.
- Sean Salmon departs as EVP Cardiovascular; Skip Kiil promoted to EVP/President Cardiovascular Portfolio; Michael Carter to lead CST.
- FY26 guidance: ~5% organic revenue growth; non-GAAP EPS $5.50-$5.60 reflecting tariff uncertainty.

## SEC filing metadata
- accession: 0001613103-25-000078
- form_type: 8-K
- ticker: MDT
- cik: 0001613103
- company_name: Medtronic plc
- filed_at: 2025-05-21T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1613103/000161310325000078/0001613103-25-000078-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1613103/000161310325000078/mdt-20250521.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001613103-25-000078
- JSON: https://secwatch.observer/filing/0001613103-25-000078.json
- Plain text: https://secwatch.observer/filing/0001613103-25-000078.txt

## Key facts
- Executive change
  Skip Kiil was appointed as EVP and President, Cardiovascular Portfolio at Medtronic plc.
  - Action: assuming
  - Role: EVP and President, Cardiovascular Portfolio
  source text: Skip Kiil would be assuming the role of EVP and President, Cardiovascular Portfolio
  evidence_url: https://www.sec.gov/Archives/edgar/data/1613103/000161310325000078/0001613103-25-000078-index.htm
- Executive change
  Sean Salmon departed as EVP and President, Cardiovascular Portfolio at Medtronic plc.
  - Action: departing
  - Role: EVP and President, Cardiovascular Portfolio
  source text: Sean Salmon would be departing from his position as EVP and President, Cardiovascular Portfolio
  evidence_url: https://www.sec.gov/Archives/edgar/data/1613103/000161310325000078/0001613103-25-000078-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.